Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection

A multiple sclerosis patient infected by SARS-CoV-2 during fingolimod therapy was hospitalized with moderate clinical features, and recovered in 15  days. High levels of CCL5 and CCL10 chemokines and of antibody-secreting B cells were detected, while the levels other B- and T-cell subsets were comparable to that of appropriate controls. However, CD4+ and CD8+ cells were oligoclonally expanded and prone to apoptosis when stimulated in vitro. T his study suggests that fingolimod-immunosuppressed patients, despite the low circulating lymphocytes, may rapidly expand antibody-secreting cells and mount an effective immune response that favors COVID-19 recovery after discontinuation.

Source: Journal of Neuroimmunology - May 27, 2020 Category: Allergy & Immunology Authors: Marco Chiarini, Simone Paghera, Daniele Moratto, Nicola De Rossi, Mauro Giacomelli, Raffaele Badolato, Ruggero Capra, Luisa Imberti Tags: Short Communication Source Type: research